tiprankstipranks
Advertisement
Advertisement
Alector to discontinue PROGRESS-AD trial of nivisnebart
PremiumThe FlyAlector to discontinue PROGRESS-AD trial of nivisnebart
24d ago
Alector upgraded to Overweight from Neutral at Cantor Fitzgerald
Premium
The Fly
Alector upgraded to Overweight from Neutral at Cantor Fitzgerald
1M ago
Alector files $400M mixed securities shelf
Premium
The Fly
Alector files $400M mixed securities shelf
2M ago
Alector reports Q4 EPS (34c), consensus (36c)
PremiumThe FlyAlector reports Q4 EPS (34c), consensus (36c)
3M ago
Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors
Premium
Company Announcements
Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors
4M ago
Alector price target raised to 90c from 75c at Morgan Stanley
Premium
The Fly
Alector price target raised to 90c from 75c at Morgan Stanley
5M ago
Alector’s Strategic and Financial Challenges Prompt Sell Rating Amid Clinical Setbacks
PremiumRatingsAlector’s Strategic and Financial Challenges Prompt Sell Rating Amid Clinical Setbacks
6M ago
Alector’s Strategic Shift to ABC Platform: Promising CNS Delivery and Neurodegenerative Disease Solutions
Premium
Ratings
Alector’s Strategic Shift to ABC Platform: Promising CNS Delivery and Neurodegenerative Disease Solutions
6M ago
Cautious Outlook on Alector Amid Strategic Shift and Uncertain Clinical Prospects
Premium
Ratings
Cautious Outlook on Alector Amid Strategic Shift and Uncertain Clinical Prospects
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100